Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets
Open Access
- 10 February 2026
- journal article
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (2)
Abstract
Immune checkpoints are critical regulatory molecules in the immune system that maintain self-tolerance by preventing excessive immune activation against healthy tissues while being exploited by malignant cells to promote tumorigenesis and metastasis through immune evasion mechanisms. Immune checkpoint inhibitors (ICIs), represented by programmed cell death protein-1 (PD-1) inhibitors, are a revolutionary class of antitumor therapeutics that have achieved remarkable clinical success over the last decade, with the application of ICIs expanding to a broader spectrum of malignancies. Nonetheless, the administration of ICIs may induce immune dysregulation, potentially leading to the development of multiple immune-related adverse events (irAEs) across various organ systems. Cardiovascular toxicities are a series of relatively rare but severe irAEs that are drawing increasing attention. This review summarizes the latest findings in immune checkpoint signaling pathways and the potential mechanisms underlying the development of various cardiovascular toxicities associated with immunotherapies. Additionally, we also evaluate advances and novel therapeutic targets in the treatment of cardiovascular toxicities.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC3606500)
- National Natural Science Foundation of China (82170489)
- National Natural Science Foundation of China (32171098)
- National Natural Science Foundation of China (82470428)
- Natural Science Foundation of Zhejiang Province (LMS25H010001)
- Natural Science Foundation of Zhejiang Province (LZ26H020001)
- Natural Science Foundation of Zhejiang Province (LMS25H020003)
- zhejiang provincial medical and health science and technology project (2025KY409)
- Project of Medical Science Research Foundation from the Health Department of Zhejiang Province (WKJ-ZJ-2312)
This publication has 197 references indexed in Scilit:
- Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case reportClinical Case Reports, 2023
- Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System databaseCancer Medicine, 2022
- Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapyEuropean Journal of Immunology, 2021
- TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer modelCancer Medicine, 2020
- Diversity of macrophage phenotypes and responses in atherosclerosisCellular and Molecular Life Sciences, 2019
- Regulatory mechanisms of PD-L1 expression in cancer cellsCancer Immunology, Immunotherapy, 2018
- Current State of knowledge on Takotsubo Syndrome: A Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2015
- Differential control of CD4+ T‐cell subsets by the PD‐1/PD‐L1 axis in a mouse model of allergic asthmaEuropean Journal of Immunology, 2015
- Interleukin‐21 modulates Th1 and Th17 responses in giant cell arteritisArthritis & Rheumatism, 2011
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DCEuropean Journal of Immunology, 2009